{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide", "query": { "intervention": "lenalidomide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 696, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T07:13:37.875Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00790842", "title": "Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Neoplasm" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Anticoagulants", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2009-01-21", "completion_date": "2018-03-08", "has_results": true, "last_update_posted_date": "2018-10-24", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ames", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00790842" }, { "nct_id": "NCT04497961", "title": "A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Dietary Intervention", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2020-08-28", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04497961" }, { "nct_id": "NCT00538824", "title": "Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2007-12", "completion_date": "2010-09-22", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538824" }, { "nct_id": "NCT01029054", "title": "Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "carfilzomib, lenalidomide plus dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2009-09", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 4, "location_summary": "Ann Arbor, Michigan • St Louis, Missouri • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01029054" }, { "nct_id": "NCT02636322", "title": "Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma Unclassifiable" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2016-03-29", "completion_date": "2022-10-24", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02636322" }, { "nct_id": "NCT05351593", "title": "Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CNS Lymphoma", "Primary Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James Rubenstein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2022-06-08", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05351593" }, { "nct_id": "NCT04566328", "title": "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma", "RISS Stage I Plasma Cell Myeloma", "RISS Stage II Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab and Hyaluronidase-fihj", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1450, "start_date": "2021-02-24", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 642, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 457 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566328" }, { "nct_id": "NCT04009109", "title": "Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma, Multiple" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Daratumumab Injection", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 79, "start_date": "2020-10-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 7, "location_summary": "Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more", "locations": [ { "city": "Bangor", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04009109" }, { "nct_id": "NCT00179699", "title": "Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "CC-5013", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2005-09", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2005-11-07", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 5, "location_summary": "Orlando, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Setauket", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00179699" }, { "nct_id": "NCT04150328", "title": "Lenalidomide Monotherapy in R/R DLBCL", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "MorphoSys AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 490, "start_date": "2019-04-12", "completion_date": "2020-08-25", "has_results": false, "last_update_posted_date": "2022-08-24", "last_synced_at": "2026-06-07T07:13:37.875Z", "location_count": 8, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Manhasset, New York + 5 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Manhasset", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150328" } ] }